Portal de Periódicos da CAPES

Estriol conjugates in body fluids in late human pregnancy

1975; Pergamon Press; Volume: 6; Issue: 5 Linguagem: Inglês

10.1016/0022-4731(75)90049-7

1878-2353

Mortimer Levitz, Helmut Jirku, Susan Kadner, Bruce K. Young,

Systemic Lupus Erythematosus Research

A new method was developed for the assay of estriol (E3) conjugates in amniotic fluid, urine and plasma of third trimester human pregnancy. Tritiated estriol-3-sulfate (E3-3S), estriol-16-glucosiduronate (E3-16G) estriol-3-glucosiduronate (E3-3G) and estriol-3-sulfate-16-glucosiduronate (E3-3S-16G) are added to the fluid. The conjugates are separated as their triethylammonium salts on Sephadex LH-20. Each conjugate is hydrolyzed enzymatically and the estriol is purified by solvent extractions. The estriol is quantitated by radioimmunoassay. In the amniotic fluid E3-16G and E3-3S-16G comprised about 75% of the total E3 conjugates. In normal pregnancy the E3-16G/E3-3S-16G ratio increased markedly with gestational age. In Rh-isoimmunization disease the ratio increased less dramatically and the patterns were erratic. In the urine E3-16G predominated (70–80%) whereas in the plasma E3-3S-16G comprised about 45% and E3-16G about 25% of the total. The concentrations of E3-3S and E3-16G were variable. The renal clearances in ml/min of the E3 conjugates measured in 2 subjects are as follows: E3-16G, 343–508 (similar to that of p-aminohippuric acid); E3-3G, 64—149; E3-3S, 13–34; and E3-3S-16G, 21—29. These methods appear applicable to the study of a variety of conditions in pregnancy in which pathology may be reflected in abnormal profiles of E3 conjugates.